Unknown

Dataset Information

0

Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis.


ABSTRACT: Background: Mycobacterium tuberculosis [Mtb] could be present in different metabolic population in the lung lesions, and nonreplicating persisters [NRP], associated with latent tuberculosis [TB], are the most difficult to kill. Objective: Test the combination of tedizolid, moxifloxacin, and faropenem for activity against NRP using Mtb SS18b in the hollow fiber model [HFS-TB]. Methods: Tedizolid and moxifloxacin were tested as, first, two-drug combination against log-phase growth [LPG] and, second, slowly replicating bacilli [SRB] under acidic condition and with faropenem to create a three-drug combination regimen. Finally, standard regimen [isoniazid-rifampin-pyrazinamide] was used as comparator in the HFS-TB experiment with NRP Mtb. HFS-TB units were sampled for drug-concentration measurement as well as for estimation of bacterial burden using solid agar and mycobacterial growth indicator tube [MGIT] method. Linear regression was used to calculate the kill slopes with each treatment regimen and analysis of variance (ANOVA) to compare the regimen. Results: Tedizolid at standard dose in combination with high-dose moxifloxacin killed 3.05 log10 CFU/ml LPG Mtb and 7.37 log10 CFU/ml SRB in the bactericidal and sterilizing activity HFS-TB experiments, respectively. There was no statistical difference between tedizolid-moxifloxacin-faropenem combination and the standard regimen as both killed 7.35 log10 CFU/ml NRP Mtb in 21 days. There was no emergence of resistance to any of the drugs studied in the three HFS-TB experiments. Conclusion: The experimental regimen of tedizolid, moxifloxacin, and faropenem could effectively kill NRP population of Mtb, and given the efficacy against different metabolic population of Mtb could serve as a pan-TB regimen. Clinical studies are warranted to validate the in vitro findings.

SUBMITTER: Srivastava S 

PROVIDER: S-EPMC7851080 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating <i>Mycobacterium tuberculosis</i>.

Srivastava Shashikant S   Cirrincione Kayle N KN   Deshpande Devyani D   Gumbo Tawanda T  

Frontiers in pharmacology 20210119


<b>Background:</b> <i>Mycobacterium</i> <i>tuberculosis</i> [<i>Mtb</i>] could be present in different metabolic population in the lung lesions, and nonreplicating persisters [NRP], associated with latent tuberculosis [TB], are the most difficult to kill. <b>Objective:</b> Test the combination of tedizolid, moxifloxacin, and faropenem for activity against NRP using <i>Mtb</i> SS18b in the hollow fiber model [HFS-TB]. <b>Methods:</b> Tedizolid and moxifloxacin were tested as, first, two-drug comb  ...[more]

Similar Datasets

| S-EPMC3914891 | biostudies-literature
| S-EPMC2944619 | biostudies-literature
| S-EPMC4468706 | biostudies-other
| S-EPMC6260150 | biostudies-literature
| S-EPMC1479142 | biostudies-literature
| S-EPMC4576094 | biostudies-literature
| S-EPMC5913991 | biostudies-literature
| S-EPMC5064158 | biostudies-literature
2021-12-15 | GSE166501 | GEO
| S-EPMC4068502 | biostudies-literature